GSK’s ratings under pressure with Novartis purchase

UK drug maker GlaxoSmithKline agreed to buy Novartis’ 36.5% stake in the pair's consumer healthcare joint venture just days after backing out of an acquisition for a similar Pfizer unit. But analysts disagree whether GSK’s ratings are being stretched to breaking point despite the new trade being far smaller.